Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

Mutational activation of BRAF is the most prevalent genetic alteration in human melanoma, with ≥ 50% of tumours expressing the BRAF(V600E) oncoprotein(1,2). Moreover, the marked tumour regression and improved survival of late-stage BRAF-mutated melanoma patients in response to treatment with vemuraf...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Thakur, Meghna Das, Salangsang, Fernando, Landman, Allison S., Sellers, William R., Pryer, Nancy K., Levesque, Mitchell P., Dummer, Reinhard, McMahon, Martin, Stuart, Darrin D.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2013
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3930354/
https://ncbi.nlm.nih.gov/pubmed/23302800
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature11814
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky